PPT-Management of NRTI Resistance

David Spach MD Principal Investigator NW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated June 8 2015 NRTI Resistance Outline Mechanism of NRTI Resistance. Jim Demarest. ,. 1. Mark Underwood,. 2. Marty St Clair,. 2. . David Dorey,. 3. Steve Almond,. 3. Robert Cuffe,. 4. . Dannae Brown,. 5. Garrett Nichols. 6. . 1. ViiV Healthcare, Global R&D, Research Triangle Park, NC, USA; . Vincent Marconi, . MD. Outline. Transmitted Drug Resistance. Acquired Drug Resistance. Transmitted Drug Resistance. Europe. North America. Japan. Australia. Europe. 23K . pts. from 75 studies in 20 countries. FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of the 95% CI for the difference = -12%, 90% power). 1. 2. old balance. new balance. change. imbalance. There is no change without resistance!. or:. „Nobody likes change – except a wet baby. “. !. Challenging new change process. shock. denial. comprehension cognitive. EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . Study. NVP vs ATV/r . ARTEN . EFV vs ATV/r . A5202. DOR vs DRV/r. DRIVE-FORWARD. Design. Objective. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, . What is pesticide resistance?. How does it occur?. Resistance to:. Insecticides. Fungicides. Herbicides. How to delay resistance. © Marlin E. Rice. What is pesticide resistance?. The population of a single kind of pest is made up of biotypes of that organism.. ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . PhD. Candidate ENVER DACI. European University Of . Tirana. e. nver_daci@hotmail.com. ABSTRACT. Change management is an important issue in today's business environment, which changes constantly. Change has become a constant for business organizations and microfinance institutions, which need to change in order to remain competitive in the market. . PhD. Candidate ENVER DACI. European University Of . Tirana. e. nver_daci@hotmail.com. ABSTRACT. Change management is an important issue in today's business environment, which changes constantly. Change has become a constant for business organizations and microfinance institutions, which need to change in order to remain competitive in the market. . Clinical Pharmacist – HIV Medicine. Outline. What is HIV?. Common Labs. Life Cycle and Medication Targets. Building an HIV regimen. HIV Guidelines. When to start treatment. What medications to start.



 \n\n
\r

\r\n \n


 
\r



 !""#
"$$%
\r 
&\n

\r
' (#
'\n 
 \n#
\r\n 

- 215 - cotton worldwide TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. Supported by an educational grant from Gilead Sciences, Inc.. Gregory D. . Huhn. , MD, MPHTM. COVID-19 Vaccination Coordinator and Senior Director of HIV Services. Cook County Health. Associate Professor, Department of Internal Medicine, Division of Infectious Disease. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg.